RIVM investigates long-term effects of coronavirus vaccine

This month, the National Institute for Public Health and Environment (RIVM) announced that it is conducting extensive research on the long-term efficacy of various coronavirus vaccines available in the Netherlands.

Does the vaccine provide long-term protection against the coronavirus?

The purpose of RIVM’s Corona Vaccination Study (VASCO) is to investigate how vaccines provide long-term protection against COVID-19 in all age groups and which vaccines are most effective. The study also examines whether these vaccines provide protection against various coronavirus variants.

VASCO will track the lives of 50,000 people between the ages of 18 and 35 in the Netherlands over the next five years. The safety and efficacy of all vaccines were investigated before they were released to the market, but only limited studies were conducted on the efficacy of vaccines in risk groups. Therefore, both healthy people and people with chronic illnesses are invited to participate in the study.

Limited information about vaccines and viruses

Little is known about how long the vaccine’s protection against coronavirus lasts, as both the virus and the vaccine are (relatively) new. However, health professionals suggest that countries around the world may need to start vaccination of older and vulnerable people again in the fall.

By clicking Subscribe, you agree that we will process your information in accordance with our privacy policy. For more information, please see this page.

RIVM investigates long-term effects of coronavirus vaccine

Source link RIVM investigates long-term effects of coronavirus vaccine

Back to top button